{"id":"W4413112190","doi":"10.1136/jitc-2025-012478","title":"Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"EMD Serono; LEO Pharma; PharmaMar; Servier; Eisai; Fred Hutchinson Cancer Research Center; Regeneron Pharmaceuticals; Springworks Therapeutics; Advanced Accelerator Applications; Incyte; Les Laboratories Pierre Fabre; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Merkel cell carcinoma; Tolerability; Internal medicine; Clinical endpoint; Phases of clinical research; Oncology; Gastroenterology; Chemotherapy; Surgery; Carcinoma; Adverse effect; Clinical trial","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001401924,0.0006784031,0.0009631512,0.0001899295,0.0002193165,0.0004506024,0.0004479484,0.0005038542,0.001620244],"category_scores_gemma":[0.0005808048,0.000279755,0.0006116107,0.00016491,0.0003330405,0.0003470176,0.0001833416,0.00118597,0.0004473417],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006496967,"about_ca_system_score_gemma":0.000866236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007529581,"about_ca_topic_score_gemma":0.002559058,"domain_scores_codex":[0.9997692,0.0001124144,0.00001184325,0.00003480567,0.00002358491,0.00004820258],"domain_scores_gemma":[0.999524,0.00008104687,0.0001284942,0.00003663329,0.00003521175,0.0001945745],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4854551,0.07627334,0.04518065,0.00148569,0.002505457,0.0007640576,0.000765058,0.004851699,0.1296471,0.0002554528,0.006912399,0.2459039],"study_design_scores_gemma":[0.3960702,0.5313695,0.05416588,0.00004876645,0.00083138,0.001124625,0.0001041004,0.002281587,0.008811578,0.0001160573,0.005044124,0.00003234311],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959264,0.001612096,0.0003719899,0.0001705315,0.00003845097,0.0008517361,0.0003737682,0.00005320904,0.0006019037],"genre_scores_gemma":[0.9957765,0.0006841224,0.0008344366,0.0003730048,0.00005024824,0.0006486494,0.0007484825,0.000009499457,0.0008751402],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001620244,"threshold_uncertainty_score":0.007414222,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01389871285557377,"score_gpt":0.3462098475511426,"score_spread":0.3323111346955689,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}